Involvement of NADPH: Cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species

Biochemical Pharmacology

Volumn 62, Issue 4, 2001, Pages 461-468

  Bailey, Susan M ^a   Lewis, Alex D ^a   Patterson, Laurence H ^c   Fisher, Geoff R ^c   Knox, Richard J ^b   Workman, Paul ^b  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c DE MONTFORT UNIVERSITY   (United Kingdom)

Author keywords

Bioreductive agents; DNA damage; Electron spin resonance spectroscopy; EO9; NADPH: cytochrome P450 reductase; Reduction

Indexed keywords

5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; 5,5 DIMETHYL 1 PYRROLINE 1 OXIDE; CATALASE; DIMETHYL SULFOXIDE; FREE RADICAL; PLASMID DNA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; SEMIQUINONE; SINGLE STRANDED DNA; SUPEROXIDE DISMUTASE;

ARTICLE; CATALYSIS; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG ACTIVATION; DRUG STRUCTURE; ELECTRON SPIN RESONANCE; NONHUMAN; PRIORITY JOURNAL; RAT; REDUCTION; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; AZIRIDINES; CATALYSIS; DNA; DNA DAMAGE; ELECTRON SPIN RESONANCE SPECTROSCOPY; FREE RADICALS; INDOLEQUINONES; INDOLES; NADPH-FERRIHEMOPROTEIN REDUCTASE; RATS;

EID: 0035882749     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(01)00674-8     Document Type: Article

References (30)

1. Mitomycin C, prototype of a bioreductive alkylating agent
2. Mitomycin analogues. I. Indoloquinones as (potential) bisalkylating agents
3. EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models
4. Lack of myelosuppression with EO9 in human and mouse bone marrow: Correlation with low DT-diaphorase
5. A randomised phase-II study with 2 schedules of the novel indoloquinone EO9 in non-small-cell-lung cancer - A study of the EORTC early clinical-studies group (ECSG)
6. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug EO9
7. Phase-II studies with EO9 in breast, colorectal, gastric, pancreatic and NSCLC
8. Bioreductive drugs into the next millennium
9. Enzyme-directed bioreductive drug development revisited: A commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase
10. Enzyme-directed bioreductive drug development
11. Reduction of the indoloquinone anticancer drug EO9 by purified DT-diaphorase: A detailed kinetic study and analysis of metabolites
12. Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: Indoloquinones and diaziridinyl benzoquinones
13. Involvement of DT-diaphorase in the DNA cross-linking and sequence selectivity of the novel indoloquinone antitumour agent EO9
14. DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas
15. The role of NAD(P)H: Quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive activation of the novel indoloquinone antitumour agent EO9
16. Catalytic properties of NAD(P)H: Quinone acceptor oxidoreductase. A study involving the mouse, rat, human, mouse-rat chimeric enzymes
17. EO9: Relationship between DT-diaphorase and response in vitro and in vivo
18. Reductase enzyme expression across the National Cancer Institute tumour-cell line panel-correlation with sensitivity to mitomycin-C and EO9
19. DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9
20. Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia
21. Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression
22. Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines
23. Unusually marked hypoxic sensitisation to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity
24. Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase
25. NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals
26. Free radical formation and DNA strand breakage during metabolism of diaziquone by NAD(P)H quinone-acceptor oxidoreductase (DT-diaphorase) and NADPH cytochrome c reductase
27. Role of NADPH: Cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C
28. The relative importance of NADPH: Cytochrome c(P450) reductase for determining the sensitivity of human tumour cells to the indoloquinone EO9 and related analogues lacking functionality in the C-2 and C-3 position
29. Spin trapping of superoxide
30. The autooxidation of reduced forms of EO9